391 related articles for article (PubMed ID: 16630403)
1. Postoperative concurrent chemoradiotherapy with mitomycin in advanced squamous cell carcinoma of the head and neck: results from three prospective randomized trials.
Rewari AN; Haffty BG; Wilson LD; Son YH; Joe JK; Ross DA; Papac RJ; Sasaki CT; Fischer JJ
Cancer J; 2006; 12(2):123-9. PubMed ID: 16630403
[TBL] [Abstract][Full Text] [Related]
2. Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial.
Haffty BG; Wilson LD; Son YH; Cho EI; Papac RJ; Fischer DB; Rockwell S; Sartorelli AC; Ross DA; Sasaki CT; Fischer JJ
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):119-28. PubMed ID: 15629602
[TBL] [Abstract][Full Text] [Related]
3. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck.
Haffty BG; Son YH; Wilson LD; Papac R; Fischer D; Rockwell S; Sartorelli AC; Ross D; Sasaki CT; Fischer JJ
Radiat Oncol Investig; 1997; 5(5):235-45. PubMed ID: 9372546
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy followed by concurrent hyperfractionated radiation therapy and sensitizing chemotherapy for locally advanced (T3-T4) oropharyngeal squamous cell carcinoma.
Finnegan V; Parsons JT; Greene BD; Sharma V
Head Neck; 2009 Feb; 31(2):167-74. PubMed ID: 18853443
[TBL] [Abstract][Full Text] [Related]
5. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.
Argiris A; Stenson KM; Brockstein BE; Mittal BB; Pelzer H; Kies MS; Jayaram P; Portugal L; Wenig BL; Rosen FR; Haraf DJ; Vokes EE
Head Neck; 2004 May; 26(5):447-55. PubMed ID: 15122662
[TBL] [Abstract][Full Text] [Related]
6. Radiation therapy with hyperbaric oxygen at 4 atmospheres pressure in the management of squamous cell carcinoma of the head and neck: results of a randomized clinical trial.
Haffty BG; Hurley R; Peters LJ
Cancer J Sci Am; 1999; 5(6):341-7. PubMed ID: 10606475
[TBL] [Abstract][Full Text] [Related]
7. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial.
Budach V; Stuschke M; Budach W; Baumann M; Geismar D; Grabenbauer G; Lammert I; Jahnke K; Stueben G; Herrmann T; Bamberg M; Wust P; Hinkelbein W; Wernecke KD
J Clin Oncol; 2005 Feb; 23(6):1125-35. PubMed ID: 15718308
[TBL] [Abstract][Full Text] [Related]
8. Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas.
Le QT; Taira A; Budenz S; Jo Dorie M; Goffinet DR; Fee WE; Goode R; Bloch D; Koong A; Martin Brown J; Pinto HA
Cancer; 2006 May; 106(9):1940-9. PubMed ID: 16532436
[TBL] [Abstract][Full Text] [Related]
9. Patterns of failure in patients with locally advanced head and neck cancer treated postoperatively with irradiation or concomitant irradiation with Mitomycin C and Bleomycin.
Zakotnik B; Budihna M; Smid L; Soba E; Strojan P; Fajdiga I; Zargi M; Oblak I; Lesnicar H
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):685-90. PubMed ID: 17197122
[TBL] [Abstract][Full Text] [Related]
10. Concomitant low-dose cisplatin and three-dimensional conformal radiotherapy for locally advanced squamous cell carcinoma of the head and neck: Analysis of survival and toxicity.
Lau H; Brar S; Hao D; MacKinnon J; Yee D; Gluck S
Head Neck; 2006 Mar; 28(3):189-96. PubMed ID: 16265658
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck.
Budach W; Hehr T; Budach V; Belka C; Dietz K
BMC Cancer; 2006 Jan; 6():28. PubMed ID: 16448551
[TBL] [Abstract][Full Text] [Related]
12. Hyperfractionated accelerated radiotherapy alone and with concomitant chemotherapy to the head and neck: treated within and outside of randomized clinical trials.
Hehr T; Classen J; Schreck U; Glocker S; Bamberg M; Budach W
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1424-30. PubMed ID: 15050319
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of primary tumor volume after concurrent chemoradiation with daily low-dose cisplatin for advanced-stage head and neck carcinoma.
Hoebers FJ; Pameijer FA; de Bois J; Heemsbergen W; Balm AJ; Schornagel JH; Rasch CR
Head Neck; 2008 Sep; 30(9):1216-23. PubMed ID: 18642295
[TBL] [Abstract][Full Text] [Related]
14. Phase II feasibility trial of adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese patients with post-operative high-risk squamous cell carcinoma of the head and neck.
Kiyota N; Tahara M; Okano S; Kawashima M; Matsuura K; Onozawa Y; Nibu K; Hayashi R; Yoshimura K; Ohtsu A
Jpn J Clin Oncol; 2012 Oct; 42(10):927-33. PubMed ID: 22923484
[TBL] [Abstract][Full Text] [Related]
15. Hyperfractionated, accelerated chemoradiation with concurrent mitomycin-C and cisplatin in locally advanced head and neck cancer, a phase I/II study.
Hehr T; Classen J; Welz S; Ganswindt U; Scheithauer H; Koitschev A; Bamberg M; Budach W
Radiother Oncol; 2006 Jul; 80(1):33-8. PubMed ID: 16875750
[TBL] [Abstract][Full Text] [Related]
16. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).
Bernier J; Cooper JS; Pajak TF; van Glabbeke M; Bourhis J; Forastiere A; Ozsahin EM; Jacobs JR; Jassem J; Ang KK; Lefèbvre JL
Head Neck; 2005 Oct; 27(10):843-50. PubMed ID: 16161069
[TBL] [Abstract][Full Text] [Related]
17. Phase II clinical trial of parenteral hydroxyurea and hyper-fractionated, accelerated external beam radiation therapy in patients with advanced squamous cell carcinoma of the head and neck: toxicity and efficacy with continuous ribonucleoside reductase inhibition.
Beitler JJ; Smith RV; Owen RP; Silver CE; Mazumdar M; Wadler S
Head Neck; 2007 Jan; 29(1):18-25. PubMed ID: 16983691
[TBL] [Abstract][Full Text] [Related]
18. Benefit of postoperative chemoradiotherapy for patients with unknown primary squamous cell carcinoma of the head and neck.
Shehadeh NJ; Ensley JF; Kucuk O; Black C; Yoo GH; Jacobs J; Lin HS; Heilbrun LK; Smith D; Kim H
Head Neck; 2006 Dec; 28(12):1090-8. PubMed ID: 16933316
[TBL] [Abstract][Full Text] [Related]
19. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.
Spencer SA; Harris J; Wheeler RH; Machtay M; Schultz C; Spanos W; Rotman M; Meredith R; Ang KK
Head Neck; 2008 Mar; 30(3):281-8. PubMed ID: 17764087
[TBL] [Abstract][Full Text] [Related]
20. Postoperative adjuvant chemoradiotherapy in older patients with head and neck cancer.
Airoldi M; Cortesina G; Giordano C; Pedani F; Gabriele AM; Marchionatti S; Bumma C
Arch Otolaryngol Head Neck Surg; 2004 Feb; 130(2):161-6. PubMed ID: 14967744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
